Schirmbeck et al., 2003 - Google Patents
Different immunogenicity of H‐2 Kb‐restricted epitopes in natural variants of the hepatitis B surface antigenSchirmbeck et al., 2003
View PDF- Document ID
- 17380953614654614013
- Author
- Schirmbeck R
- Böhm W
- Fissolo N
- Melber K
- Reimann J
- Publication year
- Publication venue
- European journal of immunology
External Links
Snippet
The small hepatitis B surface antigen (HBsAg) of hepatitis B virus (HBV) has limited variability, but some serotypes and genotypes have been defined. Although no biological or pathogenetic differences could be traced to HBV serotypes, the clinical picture, response to …
- 239000000427 antigen 0 title abstract description 28
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse Transcribing DNA Viruses
- C12N2730/00011—Reverse Transcribing DNA Viruses
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense
- C12N2770/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense ssRNA Viruses positive-sense
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kuhröber et al. | DNA vaccination with plasmids encoding the intracellular (HBcAg) or secreted (HBeAg) form of the core protein of hepatitis B virus primes T cell responses to two overlapping Kb-and Kd-restricted epitopes. | |
| Schirmbeck et al. | Similar as well as distinct MHC class I‐binding peptides are generated by exogenous and endogenous processing of hepatitis B virus surface antigen | |
| Heile et al. | Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates | |
| JP4210735B2 (en) | HLA-A2.1 binding peptide and use thereof | |
| TW201106967A (en) | Composition for treating HBV infection | |
| Schirmbeck et al. | Different immunogenicity of H‐2 Kb‐restricted epitopes in natural variants of the hepatitis B surface antigen | |
| CN87100603A (en) | Vaccines against melanoma | |
| JP2006265267A (en) | Hcv fusion protein with modified ns3 domain | |
| JP2003512826A (en) | Activation of HCV-specific T cells | |
| Whitacre et al. | Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance | |
| Schirmbeck et al. | Targeting murine immune responses to selected T cell-or antibody-defined determinants of the hepatitis B surface antigen by plasmid DNA vaccines encoding chimeric antigen | |
| Riedl et al. | Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential | |
| US8343757B2 (en) | Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use | |
| Schirmbeck et al. | Priming polyvalent immunity by DNA vaccines expressing chimeric antigens with a stress protein‐capturing, viral J‐domain | |
| Gerlich et al. | Functions of hepatitis B surface proteins | |
| Riedl et al. | Differential presentation of endogenous and exogenous hepatitis B surface antigens influences priming of CD8+ T cells in an epitope‐specific manner | |
| Gerlich et al. | Functions of hepatits B virus proteins and molecular targets for protective immunity | |
| Riedl et al. | Distinct, cross-reactive epitope specificities of CD8 T cell responses are induced by natural hepatitis B surface antigen variants of different hepatitis B virus genotypes | |
| Sällberg et al. | Characterization of humoral and CD4+ cellular responses after genetic immunization with retroviral vectors expressing different forms of the hepatitis B virus core and e antigens | |
| EP1806142B1 (en) | Method for the production of (poly)peptides by using truncated variants of the SV 40 large T antigen with an intact N terminus | |
| Riedl et al. | Priming biologically active antibody responses against an isolated, conformational viral epitope by DNA vaccination | |
| Zhu et al. | The wild-type hepatitis C virus core inhibits initiation of antigen-specific T-and B-cell immune responses in BALB/c mice | |
| Fissolo et al. | DNA vaccines prime CD8+ T cell responses to epitopes of viral antigens produced from overlapping reading frames of a single coding sequence | |
| Aguilar‐Noriega et al. | A chimeric protein encompassing hepatitis C virus epitopes is able to elicit both humoral and cell‐mediated immune responses in mice | |
| US20220411475A1 (en) | Hybrid virus-like particles and use thereof as a therapeutic hepatitis b vaccine |